SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.

Publikation

SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.

Wissenschaftlicher Artikel/Review - 14.12.2009

Kamm Christian Philipp, Mattle Heinrich Paul, De Marchis Gian Marco

Zitation

Kamm C, Mattle H, De Marchis G. SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology. Trials 2009; 10:115.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Trials 2009; 10

Veröffentlichungsdatum

14.12.2009

eISSN (Online)

1745-6215

Seiten

115

Kurzbeschreibung/Zielsetzung

Statins have anti-inflammatory and immunomodulatory properties in addition to their lipid-lowering effects. Currently, the effects of statins on multiple sclerosis are still controversial. Therefore, randomized clinical trials are needed to provide better evidence on the therapeutic potential of statins in multiple sclerosis. The SWiss Atorvastatin and Interferon Beta-1b trial in Multiple Sclerosis (SWABIMS) evaluates the efficacy, safety and tolerability of atorvastatin 40 mg per os daily and subcutaneous interferon beta-1b every other day compared to monotherapy with subcutaneous interferon beta-1b every other day in patients with relapsing-remitting multiple sclerosis.